Safety and efficacy of indobufen versus aspirin for cerebral small vessel disease: A randomized, double-blind, double-dummy, multicenter (SEIAS) trial protocol
Advanced Neurology · 07.07.2026 · 5 (3) · 026140005
DOI: 10.36922/an026140005 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Advanced Neurology, online erschienen am 07.07.2026. Verfasst von Ying Chen und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Indobufen, a reversible multi-target platelet aggregation inhibitor with anticoagulant properties, has been shown to reduce the risk of ischemic cardiovascular and peripheral vascular diseases. However, its efficacy and safety in patients with imaging-confirmed cerebral small vessel disease (CSVD) remain unclear. This trial protocol aims to compare the efficacy and safety of indobufen versus aspirin in patients with imaging-confirmed CSVD. We will conduct a randomized, double-blind, double-dummy, multicenter trial at 16 stroke centers in China. A total of 1,042 eligible patients will be randomly assigned in a 1:1 ratio to receive either indobufen (100 mg twice daily) or aspirin (100 mg once daily) for one year and will be followed for a total of three years. Randomization will be centrally generated by computer and stratified by participating center. The primary endpoint is the occurrence of new lacunar infarctions detected by neuroimaging within one year. Secondary endpoints include other ischemic vascular events (e.g., transient ischemic attack and myocardial infarction), cognitive impairment, and incident dementia. The primary safety outcome is hemorrhagic complications during follow-up.
Zitieren
APA
Chen, Y., Ji, B., Cheng, Y., Zhang, Q., & Xu, Y. (2026). Safety and efficacy of indobufen versus aspirin for cerebral small vessel disease: A randomized, double-blind, double-dummy, multicenter (SEIAS) trial protocol. Advanced Neurology, 5(3), 026140005. https://doi.org/10.36922/an026140005
Vancouver
Chen Y, Ji B, Cheng Y, Zhang Q, Xu Y. Safety and efficacy of indobufen versus aspirin for cerebral small vessel disease: A randomized, double-blind, double-dummy, multicenter (SEIAS) trial protocol. Advanced Neurology. 2026;5(3):026140005. doi:10.36922/an026140005
BibTeX
@article{Chen2026,
author = {Chen, Ying and Ji, Biying and Cheng, Yue and Zhang, Qingxiu and Xu, Yun},
title = {Safety and efficacy of indobufen versus aspirin for cerebral small vessel disease: A randomized, double-blind, double-dummy, multicenter (SEIAS) trial protocol},
journal = {Advanced Neurology},
year = {2026},
volume = {5},
number = {3},
pages = {026140005},
doi = {10.36922/an026140005}
}
EUVIMED